Supplementary data

Overall summary of subject incidence of treatment-emergent adverse events in double-blind phase

	Cinacalcet (N = 33)	**Placebo (N = 34)**
Subjects with treatment-emergent adverse events, n (%)	**27 (81.8)**	**20 (58.8)**
Serious adverse events	3 (9.1)	4 (11.8)
Leading to discontinuation of investigational product	2 (6.1)	1 (2.9)
Leading to discontinuation from study	0 (0.0)	1 (2.9)
Fatal adverse events	1 (3.0)	0 (0.0)
Subjects with treatment-related treatment emergent adverse events, n (%)	**14 (42.4)**	**8 (23.5)**
Serious adverse events	0 (0.0)	0 (0.0)
Leading to discontinuation of investigational product	1 (3.0)	0 (0.0)
Leading to discontinuation from study	0 (0.0)	0 (0.0)
Fatal adverse events	0 (0.0)	0 (0.0)
Identified risks, n (%)		
Hypocalcemia	0 (0.0)	0 (0.0)
Seizure/convulsions	0 (0.0)	0 (0.0)
Hypotension	1 (3.0)	1 (2.9)
Cardiac failure	0 (0.0)	0 (0.0)
Hypersensitivity	0 (0.0)	1 (2.9)
Potential risks, n (%)		
Acute pancreatitis	0 (0.0)	0 (0.0)
Drug-related hepatic disorders	1 (3.0)	0 (0.0)
Fractures	3 (9.1)	1 (2.9)
Ischemic heart disease	0 (0.0)	1 (2.9)

Nervous system disorders	7 (21.2)	7 (20.6)
Ventricular tachyarrhythmias	0 (0.0)	0 (0.0)
Subjects reporting events adjudicated by the CEC, n (%)	**1 (3.0)**	**1 (2.9)**
Death	1 (3.0)	0 (0.0)
Hospitalization for unstable angina	0 (0.0)	1 (2.9)
Events confirmed by adjudication, n (%)	**1 (3.0)**	**0 (0.0)**
Death	1 (3.0)	0 (0.0)